Landmark Bio PBLLC

https://www.landmarkbio.com

LinkedIn: https://www.linkedin.com/company/landmarkbio

Formerly known as the new center for advanced biological innovation and manufacturing (or “CABIM”), Landmark Bio, PBLLC is a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today’s cutting-edge research into tomorrow’s breakthrough therapies. The cross-sector partnership harnesses world-leading expertise to accelerate fast-emerging and promising science, the challenges of which are daunting for any single institution to tackle alone. Board members include leaders from Harvard University, Massachusetts Institute of Technology (MIT), FUJIFILM Diosynth Biotechnologies (FDB), Cytiva, and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, the Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Massachusetts Life Sciences Center. *

	Start	2021-07-29 start jv
	Industry	contract manufacturing (biologicals)
	Industry 2	cell and gene therapy manufacturing (CGT manufacturing)
	Person	Zheng, Ran (Landmark Bio 202107– CEO before Orchard Therapeutics + Amgen + Diosynth + Genzyme)
	Person 2	Ligner, Emmanuel (General Electric 201812 President + CEO GE Healthcare Life Sciences)

	Region	Watertown, MA
	Country	United States (USA)
	Street	300 North Beacon Street
	City	02472 Watertown, MA
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Landmark Bio PPLLC. (7/29/21). "Press Release: Introducing Landmark Bio and Appointment of Ran Zheng as CEO". Watertown, MA.

		Record changed: 2024-06-07